Gout, hyperuricaemia, sleep apnoea-hypopnoea syndrome and vascular risk
Miguel Cantalejo Moreira1, Raúl María Veiga Cabello, Vanesa García Díaz
1Unidad de Reumatología, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain. mcantalejo.hflr@salud.madrid.org
Insights
Patients with gout and hyperuricaemia and suspected sleep apnoea-hypopnoea syndrome (SAHS) show higher rates of cardiovascular risks and atherothrombosis. These individuals also present with more severe SAHS compared to osteoarthritis patients.
Area of Science:
- Rheumatology
- Sleep Medicine
- Cardiology
Background:
- Gout and hyperuricaemia are associated with cardiovascular (CV) and atherothrombotic risks.
- Sleep apnoea-hypopnoea syndrome (SAHS) is increasingly recognized as a comorbidity impacting CV health.
- The relationship between gout, hyperuricaemia, SAHS, and CV outcomes requires further investigation.
Purpose of the Study:
- To evaluate cardiovascular and atherothrombosis risk factors in patients with gout and hyperuricaemia suspected of having SAHS.
- To compare these risk factors against a control group of patients with osteoarthritis (OA) and confirmed SAHS.
Main Methods:
- Clinical data on CV risk factors and atherothrombosis were collected from patients with gout and hyperuricaemia.
- Polysomnography was used to confirm SAHS diagnosis, measuring the apnoea-hypopnoea index (AHI) and oxygen saturation (SaO2).
- A control group of OA patients with confirmed SAHS was included for comparison.
Main Results:
- Gout patients (77.8%) exhibited higher prevalence of CV risk factors and atherothrombosis (46.3%) compared to OA patients (66.7% and 0%, respectively).
- SAHS was confirmed in 88.9% of gout patients, with a higher proportion experiencing moderate to severe forms.
- Lower SaO2 levels were observed in the gout group (90.18%) versus the OA group (91.26%).
Conclusions:
- A significant proportion of gout and hyperuricaemia patients with suspected SAHS were confirmed to have the condition.
- Gout patients demonstrated a greater burden of CV risk factors, atherothrombosis, and more severe SAHS compared to the OA control group.
- These findings highlight the critical link between gout, hyperuricaemia, SAHS, and cardiovascular/atherothrombotic disease.
Objective:
This study aimed to evaluate cardiovascular (CV) and atherothrombosis risk factors in patients with gout and hyperuricaemia with suspected sleep apnoea-hypopnoea syndrome (SAHS) compared with a control group of subjects with knee OA and SAHS.
Methods:
Clinical information on CV risk factors and atherothrombosis was collected in a rheumatology department in patients with gout and hyperuricaemia and suspicion of SAHS. Confirmation polysomnography that registered apnoea-hypopnoea index (AHI) and oxygen saturation during sleep (SaO2) was performed. The control group consisted of patients with OA and polysomnographically confirmed SAHS.
Results:
In the gout patient group (54 patients, 48 men), CV risk factors were found in 77.8% and evidence of atherothrombosis in 46.3%. In the OA group (36 patients, 27 men), CV risk factors were found in 66.7% and evidence of atherothrombosis in 0%. SAHS diagnosis was confirmed by polysomnography in 88.9% of patients. AHI showed mild, moderate and severe SAHS in 12%, 26% and 66% of the gout patients and 45%, 24% and 30% of the OA patients, respectively. SaO2 was 90.18% in the gout group and 91.26% in the OA group.
Conclusion:
Patients with gout and hyperuricaemia and suspicion of SAHS had polysomnographically confirmed SAHS in 88.9% of cases. These patients had more severe forms of SAHS and a greater prevalence of documented atherothrombotic disease compared with a control group with OA.
Related Concept Videos
Sleep Apnea
The condition is more prevalent among...
Chronic Kidney Disease II: Clinical Manifestations
Coronary Artery Disease I: Introduction
Nursing Assessment of the Genitourinary System I: Health History
Other Pulmonary Disorders
Cardiovascular Drugs: Classification based on Therapeutic Indications
